BIBN 99
BIBN 99 is a synthetic compound that has been studied for its potential use in the treatment of various neurological disorders. It is primarily known for its role as a selective antagonist of the neurokinin 1 receptor (NK1 receptor), which is involved in the modulation of pain and inflammation.
Chemical Structure and Properties[edit | edit source]
BIBN 99 is a small molecule with a complex chemical structure designed to specifically bind to the NK1 receptor. The molecular formula of BIBN 99 is C_33H_35N_5O_4, and it has a molecular weight of 569.67 g/mol. The compound is characterized by its high affinity for the NK1 receptor, which is a member of the tachykinin receptor family.
Mechanism of Action[edit | edit source]
BIBN 99 functions as an antagonist at the NK1 receptor, which is a G-protein coupled receptor (GPCR) that binds the neuropeptide substance P. By blocking the action of substance P, BIBN 99 can inhibit the transmission of pain signals in the central nervous system. This makes it a potential candidate for the development of new analgesic drugs.
Pharmacological Effects[edit | edit source]
Studies have shown that BIBN 99 can effectively reduce pain and inflammation in animal models. It has been investigated for its potential use in treating conditions such as migraine, chronic pain, and inflammatory diseases. The compound's ability to selectively target the NK1 receptor without affecting other receptors is a significant advantage, as it reduces the likelihood of side effects.
Clinical Applications[edit | edit source]
While BIBN 99 has shown promise in preclinical studies, its clinical development has been limited. Further research is needed to fully understand its pharmacokinetics, safety profile, and therapeutic efficacy in humans. However, its mechanism of action suggests that it could be beneficial in treating a variety of conditions associated with pain and inflammation.
Research and Development[edit | edit source]
Ongoing research is focused on optimizing the pharmacological properties of BIBN 99 and exploring its potential in combination therapies. Scientists are also investigating its effects on other neurological pathways and its potential role in neurodegenerative diseases.
Also see[edit | edit source]
Template:Receptor pharmacology
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
